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«Ὀκόσα φάρμακα οὐκ ἰῆται, σίδηρος ἰῆται˙ ὅσα σίδηρος οὐκ ἰῆται, πῦρ ἰῆται˙ ὅσα δέ 
πῦρ οὐκ ἰῆται, ταῦτα χρή νομίζειν ἀνίατα» 
Those who cannot be cured by medications can be cured by surgery, what surgery cannot 
cure, is being cured by cauterization, what cauterization cannot cure, they should be 
considered incurable 
                                                                                                           Hippocrates 460-377 BC 
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ABSTRACT 
Background: The effects of Roux-en-Y gastric bypass (GBP) have not been adequately 
explored in patients with concurrent obesity and type 2 diabetes mellitus (T2DM) to the same 
extent as has occurred for individuals with obesity alone. The overall aim of this thesis is to 
thoroughly examine the effects of GBP surgery in patients with obesity and T2DM in terms of 
cardiovascular disease and mortality, changes in various comorbidities, risk factors, and renal 
function as well as reporting adverse events. 
Method: The reported studies are based mainly on merging data from two nationwide quality 
registries in Sweden (the National Diabetes Register and Scandinavian Obesity Surgery 
Register) as well as other national databases. Our study population of individuals with T2DM 
who had undergone GBP was matched with respect to baseline parameters such as sex, age, 
body mass index (BMI), and calendar year with controls who did not undergo surgery. The 
risks of postoperative outcomes were assessed using Cox regression models adjusted for 
various factors depending on endpoints. 
Results: Assessing data for 6,132 patients in each group from 2007 to 2014, we found a 58% 
relative risk reduction in overall mortality, a 59% lower risk of cardiovascular death, and a 
49% lower risk of fatal or non-fatal myocardial infarction in the GBP group compared to 
controls. Following GBP, there were beneficial changes in BMI, hemoglobin A1c, blood 
lipids, and blood pressure compared to controls despite less frequent use of antidiabetic, 
antihypertensive, and antihyperlipidemic medications. The improvements in risk factors 
might contribute to the reduction of mortality risk after GBP in individuals with obesity and 
T2DM, but the main effect seems to be mediated through the decrease in BMI.  
New analyses of data for 5,321 individuals during 2007 to 2015 confirmed lower incidences 
of all-cause mortality and cardiovascular disease, demonstrated beneficial effects on severe 
kidney disease, and showed increased risks (2-fold to 9-fold) for several short-term 
postsurgical complications compared to controls. There were long-term adverse consequences 
of GBP compared to controls: there was a 92% higher risk of anemia, a 3-fold increase in 
nutritional deficiencies, a 33% higher risk for psychiatric diagnoses, and a 3-fold increase in 
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alcohol abuse. The risk rates for most outcomes relating to renal function were lower after 
GBP. Risks of a composite of severe renal disease or halved estimated glomerular filtration 
rate (eGFR), and cardiovascular and renal mortality, were generally lower after GBP in all 
eGFR strata, even in patients with the lowest eGFR. 
Conclusion: The benefits of GBP for patients with obesity and T2DM on mortality, 
cardiovascular risk, and a broad spectrum of clinical diagnoses might be associated to 
changes in several risk factors; however, the main effect seems to be mediated through weight 
reduction. Interestingly, the positive effects of GBP are found for almost all categories of 
renal function, at the same time delaying deterioration to end-stage renal disease. However, 
the panorama of both short- and long-term adverse events suggests a more effective selection 
of patients who genuinely are eligible for such an intervention. 
Keywords: Gastric bypass; bariatric surgery; obesity; type 2 diabetes mellitus; cardiovascular 
disease; mortality; risk factors; renal disease; adverse events 
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SAMMANFATTNING PÅ SVENSKA 
 
Bakgrund: Effekterna av Roux-en-Y gastric bypass, den mest etablerade fetmakirurgiska 
metoden, har mestadels utvärderats vid fetma men inte tillräckligt hos personer med samtidig 
typ 2-diabetes mellitus. Det övergripande syftet är att noggrant utforska effekterna av denna 
behandlingsmetod hos patienter med fetma och typ 2-diabetes gällande hjärtkärlsjukdom och 
mortalitet, förändringar i olika komorbiditeter, riskfaktorer och njursjukdom samt 
förekomsten av sidoeffekter. 
Metoder: Studierna baseras främst på samkörning av två rikstäckande kvalitetsregister i 
Sverige, Nationella Diabetesregistret och Scandinavian Obesity Surgery Register samt andra 
nationella databaser. Våra studier omfattar individer med diabetes som hade genomgått Roux-
en-Y gastric bypass matchade med patienter med fetma och diabetes som inte genomgått 
kirurgisk behandling. Riskerna för postoperativa utfall värderades med Cox 
regressionsmodeller. 
Resultat: Vi identifierade och följde 6132 patienter i två grupperna från år 2007 till 2014. 
Risken för total mortalitet var 58% lägre, för hjärtkärlsjukdom 59% lägre och för dödlig eller 
icke-dödlig hjärtinfarkt 49% lägre i den opererade gruppen jämfört med kontrollerna. Roux-
en-Y gastric bypass hade positiv påverkan på vikten, HbA1c, blodlipider och blodtryck 
jämfört med kontrollerna trots färre glukosänkande, blodtrycks- och lipidsänkande 
behandlingar. Dessa förbättringar i olika riskfaktorer kan bidra till att lägre mortalitet hos 
individer med fetma och diabetes, men den huvudsakliga effekten förefaller förmedlas genom 
viktminskningen i sig.  
Vi genomförde nya analyser med data från 2007 till 2015, då vi identifierade 5321 individer 
med fetma och typ 2-diabetes som genomgick Roux-en-Y gastric bypass. Vi bekräftade lägre 
risk för total dödlighet och kardiovaskulär sjukdom, men påvisade också fördelaktiga effekter 
på allvarlig njursjukdom. Vi visade också 2- till 9-faldigt ökade risker för sjukhusinläggning 
för flera postoperativa komplikationer. På lång sikt sågs 92% högre risk för anemi, tre gånger 
ökad risk för malnutritionstillstånd, 33% högre risk för psykiatriska diagnoser och tre gånger 
ökad risk för alkoholrelaterade tillstånd jämfört med kontrollgruppen. Förekomsten av olika 
njurrelaterade tillstånd var lägre efter Roux-en-Y gastric bypass. Riskerna för sammansatt 
utfallsmått av allvarlig njursjukdom eller halverad beräknad njurfunktion, men också för 
kardiovaskulär och mortalitet relaterad till njursjukdom, var i allmänhet lägre efter Roux-en-Y 
gastric bypass oavsett njurfunktionsnivå jämfört med de icke kirurgiskt behandlade 
patienterna. 
Konklusion: Fetmakirurgisk behandling med Roux-en-Y gastric bypass för patienter med 
fetma och typ 2-diabetes mellitus har visat positiva effekter avseende mortalitet, 
kardiovaskulär risk och ett brett spektrum av kliniska diagnoser. Gynnsamma förändringar av 
flera riskfaktorer ses, men den huvudsakliga effekten förefaller medieras av viktminskningen. 
De positiva effekterna av Roux-en-Y gastric bypass ses vid alla njurfunktionsnivåer och 
förefaller bevara njurfunktionen. Riskerna för oönskade sidoeffekter på kort och lång sikt är 
argument för ännu effektivare urval av patienter inför kirurgisk fetmabehandling, och 
strukturerad uppföljning postoperativt. 
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1. INTRODUCTION 
 
Obesity started to be a problem for humanity when it was realized that it was 
associated with different public health scourges and later when it was found that the 
mortality due to obesity surpassed the incidence of death due to starvation (1). 
Obesity, as a chronic disease, escalated to a global epidemic in parallel with economic 
development, lifestyle changes, and the altered dietary as well as physical habits of 
modern individuals. It is a complex phenomenon based on diverse genetic, behavioral, 
environmental, and socioeconomic factors, which are found in both developed and 
developing countries. The increasing prevalence of different morbidities and 
consequent mortality is the main problem of obesity, contributing to socioeconomic 
consequences worldwide. 
Overweight and obesity was considered to be a sign of prosperity and fertility in 
prehistoric and historic periods, as only the wealthy were able to achieve this 'status'. 
In the Greco-Roman period, obesity started to be perceived as exceptional rather than 
a normal condition.  Obesity often generated irony and sarcasm, and assumed the 
characteristics of caricature and satire, confirming the pattern of an idle person. The 
ancient Greeks were the first to realize the dangers of obesity and its association with 
disease. The Greek physician Hippocrates understood that the health risks of obesity 
led to infertility and early death, and recommended diet, exercise, lifestyle change, 
and use of emetics and cathartics. These recommendations have actually remained 
unchanged to the present day, when increased urbanization, sedentary working 
conditions, and availability of processed and high amounts of food have led to a sharp 
increase in obesity. It is tragic that all this development opposes the maintenance of 
ideal body weight and creates a further need for more effective methods of weight 
loss. The management of obesity also involves its associated co-morbidity, which 
includes diabetes. 
This thesis examines the medical control of obesity and diabetes through gastric 
bypass surgery intervention with respect to effectiveness and potential problems. 
 
Obesity: definition, epidemiology, and associated factors 
Obesity is simply defined as excess body weight for height, but this definition 
provides a false impression when considering obesity as a disease (2). Practically, it 
only takes into account body mass index (BMI), the metric definition of obesity, 
rather than the nature of disease. At this point the criticism of the definition of obesity 
as a disease is referred to BMI, which introduced for its association to mortality 
without taking into consideration possible underlying biological mechanisms or body 
composition (3). BMI  cannot define either "excessive fat accumulation" or related 
functional impairments, as World Health Organization (WHO) presents. BMI was 
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introduced in 1832 by Quetelet to quantify obesity as there is a curvilinear relation 
between this scoring system and the proportion of body fat (4), constituting until 
nowadays the way of expression underweight (BMI < 18.5 kg/m²), normal weight 
(18-24.9 kg/m²), overweight (25-29.9 kg/m²) and obesity (>30 kg/m²). To define 
obesity as a disease, the health status of the individual needs to be assessed by clinical 
characterization, laboratory and endocrine measurements, and body adiposity 
distribution and composition (5). More simply, we approach obesity through the 
prism of BMI because of its relationship with mortality for BMI values >25 kg/m², as 
indicated by large epidemiological studies (6-10). Specifically, one of these studies 
found that persons who were overweight or had class I obesity did not have a 
significant increase in mortality risk (7), while most studies presented a J-shaped 
association of BMI with all-cause mortality (mainly resulting from major 
cardiovascular events, cancer, and respiratory diseases) and an inverse association 
regarding mental, behavioral, and accidental events for BMI between 24 and 27 kg/m² 
(8). 
According to WHO (11), the prevalence of obesity has nearly tripled between 1975 
and 2016, to 1.9 billion overweight adults and 650 million with obesity. In Europe, 
23% of women and 20% of men have been estimated to have obesity, while the 
proportion in Sweden was 17.3% and 19.9%, respectively. The prevalence of obesity 
in individuals >20 years of age was 18.6% according to WHO in 2013. This compares 
to 39.8% in the USA for corresponding statistics in 2016. A recent study (12) showed 
that trends in BMI have flattened in many high-income countries, while they continue 
increase in developing countries, independently of sex or age. 
Obesity occurs from a complex relationship of biologic, psychosocial, and behavioral 
factors resulting from genetic predisposition, socioeconomic status, and cultural 
influences. Naturally, the imbalance of incoming energy versus expenditure plays its 
role but it is not a sufficient condition for weight gain. Overfeeding studies (13) have 
highlighted that there is a significant concordance in weight gain among twin pairs as 
well as a high degree of similarity in adipose tissue distribution (14), which is likely 
to be caused by genetic and epigenetic factors. Genetic susceptibility within a 
population seems to determine those who have the possibility to manifest obesity 
when environmental factors are also fulfilled. Identification of those genes should 
provide insights into the pathophysiological mechanisms of higher BMI and 
differentiation of fat distribution. Most genetic studies have concentrated on single-
nucleotide polymorphisms and short insertions or deletions that influence a genomic 
product. The first monogenic studies have demonstrated the role of the appetite-
regulating leptin-melanocortin pathway in the central nervous system in body weight 
gain (15). In recent years, genetic biobanks have been developed, from which large 
genome-wide association studies have identified more than 300 genetic loci in 
relation to obesity, while an epigenetic focus on DNA methylation and histone 
modification has tried to establish associations with different gene expressions that 
might affect adiposity phenotype (16, 17). Although, the research on genetics 
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develops with significant associations, the genetical effects on BMI variations or 
waist-to-hip ratio cannot contribute more than 20%-25% (18, 19). 
Predictions on interactions between genes and environmental factors are difficult to 
make. Factors such as physical activity, metabolic rate, or regulation of energy 
balance by paracrine hormones, neurotransmitters, gut-brain peptides, and appetite 
modulators all play a role in fat deposition, but with unknown proportions with 
respect to causality (20). The role of gut microbiota and its composition is also being 
investigated with respect to effects on nutrient metabolism, energy balance, and BMI 
(21). Finally, cultural characteristics, high-fat diets, and different types and deposition 
patterns of adipose tissue have also been considered as important factors, with the 
latter – accumulation of visceral adipose tissue – being the focus of metabolic 
abnormalities known as metabolic syndrome. 
 
Clinical features and complications of obesity – a link to type 2 diabetes mellitus 
Hippocrates wrote "Corpulence is not only a disease itself, but the harbinger of 
others", recognizing that obesity is a medical disorder that also leads to many 
comorbidities, deteriorates quality of life, and reduces life expectancy. 
Obesity is an integral part of a cluster of metabolic abnormalities called metabolic 
syndrome including insulin resistance (22), dyslipidemia (23), and hypertension (24) 
that together culminate in an increased risk of type 2 diabetes mellitus (T2DM) and 
cardiovascular disease (CVD) (25). Specifically, increased visceral fat is accompanied 
by increased lipolysis, which leads to increased gluconeogenesis and, further, to 
hyperinsulinemia and decreased muscle insulin sensitivity. When compensation by β-
cells becomes insufficient, hyperglycemia and T2DM occur (26). A meta-analysis of 
18 prospective studies (27) demonstrated a 7-times higher risk of diabetes in persons 
with obesity and a 3-times higher risk in overweight individuals compared to those 
with normal weight. The strongest and most linear association of weight gain 
appeared for T2DM, although there were also associations with other major chronic 
diseases such as CVD and cancer as well as non-traumatic death (28). Conversely, 
individuals who were classified as metabolically healthy subjects with obesity were 
younger, with smaller waist circumference, and were associated with a lower risk for 
diabetes and CVD. Only one third of these individuals changed to a high-risk 
phenotype (29). 
The cardiovascular consequences of obesity have been highlighted in several studies 
(25, 30, 31) as well as the association with higher risk of all-cause mortality (8-10). 
Stratification into different age groups showed that adults with obesity had earlier 
onset of CVD, a greater proportion of lives exposed to CVD morbidity, and shorter 
survival than normal-weight individuals (31). For each 5 kg/m² increase in BMI above 
25 kg/m², all-cause mortality increases by 30% with the highest proportion attributed 
to CVD, diabetes, kidney disease, non-neoplastic hepatic disease, neoplastic disease, 
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and respiratory disturbance (9). Diabetes and obesity are powerful predictors of 
cardiovascular morbidity and mortality, which is related to atherosclerotic disease, the 
inflammatory status of obesity, and elevated adrenal activity with an upregulated 
renin-angiotensin-aldosterone system (32, 33). The underlying pathophysiological 
mechanism is complex. 
The combination of obesity and T2DM also seems to be responsible for an increased 
incidence of cancer. It is estimated that approximately 6% of cancer diagnoses 
worldwide in 2012 were attributed to diabetes and high BMI with higher incidences 
of liver and esophageal adenocarcinomas as well as endometrial cancers (34). The 
proposed mechanism is similarly complex to that proposed for increased CVD with 
hyperinsulinemia and the chronic inflammatory burden appearing to act in the 
pathogenesis. There are several other clinical conditions that have been attributed to 
the combination of obesity and T2DM where the mechanism is not fully understood. 
For example, osteoarthritis is a clinical complication of both obesity and diabetes, but 
also of each disease separately (35). Literature contains many other clinical 
complications related to obesity such as restrictive lung disease, hypoventilation, 
sleep apnea, gastrointestinal and liver consequences, fertility and menstruation 
problems, and neurological and psychiatric disorders. A lot of these conditions are 
also associated with T2DM. 
 
Type 2 diabetes mellitus – before the link with obesity 
T2DM is simply characterized by insulin resistance and impaired insulin secretion. It 
is a complex disease that involves cellular and molecular mechanisms leading to 
dysregulated glucose homeostasis. Multiple factors including genetic predisposition, 
insulin resistance, increased insulin secretory demand, dysregulation of glucose and 
lipid metabolism, impaired incretin release/action, amylin accumulation, and 
decreased β-cell mass play a causative role in progressive β-cell dysfunction and 
inadequate insulin secretion (36, 37). 
According to WHO in 2016, the number of individuals living with diabetes has almost 
quadrupled since 1980 to 422 million adults globally (38). Estimations from the 
International Diabetes Federation indicate that the number with diabetes will increase 
to 642 million (uncertainty interval 521-829 million) by 2040, while the number of 
deaths attributable diabetes was 5.0 million between 1990 to 2015 (39). In Europe, 66 
million people suffer of diabetes which translates to a prevalence of 9.1% and an age-
adjusted estimate of 6.7%. In Sweden, it is estimated that the prevalence of diabetes 
will rise from 6.8% in 2013 to 10.4% by 2050, with 940,000 subjects affected and a 
constant incidence of 4.4 per 1,000 (40). T2DM is the most common type of diabetes, 
accounting for around 90% of all cases of diabetes. All this data confirms the large 
burden of diabetes, especially in developing countries, and emphasize the problem for 
the future. 
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As previously mentioned, diabetes is a multifactorial disease in which genetic factors 
play a key role; at the same time, there is considerable heterogeneity. A positive 
family history contributes to 2.4-fold higher risk for diabetes, while twin studies 
provide higher concordance rates and risks (37). The complexity of diabetes genetics 
has been demonstrated by genome-wide association studies, which have shown more 
than 100 genetic associations for the phenotype (41). 
A positive energy balance with excess carbohydrate intake leads to high conversion of 
fat in the liver. Fat increases in fat tissue as well as in the liver when accumulation in 
subcutaneous adipose storage surpasses a certain threshold. This also increases 
circulating fat in the form of very low density lipoproteins and does not suppress the 
production of insulin. Over time, hyperinsulinemia further increases lipogenesis, 
deregulates pancreatic β-cells, and deteriorates peripheral tissue sensitivity, leading to 
hyperglycemia and impaired postprandial insulin secretion. The inhibitory effects of 
fatty acids and glucose on the islets reach a trigger level where the β-cells become 
unable to compensate for insulin resistance, leading to a relatively sudden onset of 
clinical diabetes (42, 43). The individual processes in the mechanism of diabetes 
development are certainly more complicated, not fully understood, and outside the 
scope of this thesis. 
 
Treatment of obesity and T2DM – the role of bariatric surgery 
The close relationship and the development of obesity and diabetes also imply 
common methods for treatment. Prevention and treatment of the combination of 
obesity and diabetes – also called diabesity (44) – is an imperative with clinical and 
economic public health consequences globally. All treatment strategies have more or 
less concentrated on weight reduction with lifestyle, medical, or surgical intervention. 
The Look AHEAD Study, for example, randomized 5,145 patients with obesity and 
diabetes to intensive lifestyle intervention through decreased caloric intake and to 175 
minutes of moderate-intensity physical activity every week over a median 10.2-year 
follow-up. It showed a significant initial weight reduction of 7%-10% followed by 
gradual regain, improvements in CVD risk factors (45, 46), and a reduction in CVD 
morbidity depending on the magnitude of weight loss (47, 48). A systematic review 
looked at the maintenance of weight loss in adults with obesity and assessed the 
evidence for the effectiveness of behavioral lifestyle interventions (49). The evidence 
was limited beyond 24 months after the initial weight loss even after addition of 
weight-loss medication, orlistat, which partially prolonged the effect but with 
inhomogeneous final results. Use of liraglutide, a glucagon-like peptide-1 (GLP-1) 
receptor agonist, in the LEADER Study (50) also showed greater weight loss (6.1% at 
160 weeks) and reduced risk for T2DM, but this was limited by the short follow-up 
duration and adverse events from the medication. Recently, a randomized, placebo-
controlled, double-blind study (CAMELLIA-TIMI 61) examined the effect of 
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lorcaserin, a selective serotonin 2C receptor agonist, that influences appetite (51). 
After a median 3.3-year follow-up, lorcaserin resulted in improvements in glycated 
hemoglobin A1c (HbA1c), which was related to weight loss (5% at the first year), 
discontinuation of antidiabetic agents, and a lower risk for microvascular outcomes 
based mainly on the effects on microalbuminuria. Actually, there are several other 
studies providing evidence of weight loss based on conservative therapies, however 
emphasizing also the limitations (52, 53). 
Bariatric or metabolic surgery is the most effective treatment for obesity and T2DM 
in the terms of maintenance of weight loss, impact on comorbidities, improvement of 
quality of life, and reduction of all-cause mortality (54-56). Surgeons hypothesized 
that shortening of the intestine should have an effect on weight loss. In 1952, a 
Swedish surgeon, Dr Viktor Henrickson, performed the first bariatric operation after 
his observation of weight reduction in patients that underwent intestine surgical 
treatment for other diseases. Historically, there have been six dominant procedures in 
bariatric surgery. In chronological order, they are jejunoileal bypass, Roux-en-Y 
gastric bypass (GBP), vertical banded gastroplasty, biliopancreatic diversion and its 
variation duodenal switch, adjustable gastric banding, and sleeve gastrectomy (SG) 
(57, 58). Because of unacceptable complications of jejunoileal bypass, Dr Mason 
developed the technique of GBP in 1967, which is actually a development of Billroth 
II resection and constitutes the most common and effective method used today. 
Comparisons with SG have demonstrated heterogeneous results. The STAMPEDE 
Study (59), for example, found higher weight reduction in GBP patients at 5 years. 
However, there was no significant difference between the methods with respect to 
glycemic control, although use of antidiabetic medication was lower in the GBP 
group. There were no significant differences with respect to blood pressure and low-
density lipoprotein (LDL)-cholesterol, while adverse events were relatively similar 
between the techniques. Likewise, the SLEEVEPASS Study (60) showed greater 
percentage weight loss among GBP patients; however, 8.3% of SG patients needed 
reoperation compared to 15.1% for GBP. A Swiss study that also randomized patients 
to the two techniques did not show significant differences in weight or metabolic 
changes (61), although there was a higher rate of reoperation/intervention among 
those who received GBP. SG seems to gaining ground in surgeons' preferences, 
mostly due to lower complication rates, despite the lack of confirmation of long-term 
efficacy. 
 
Gastric bypass – effects on weight, comorbidities, and mortality 
This thesis concentrates on the effects of GBP because it was the dominant technique 
used during the study period as well as for the completeness and availability of the 
data in Sweden. In practice, the indications for bariatric surgical treatment and GBP 
have been in accordance with the Interdisciplinary European Guidelines on Metabolic 
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and Bariatric Surgery (62), the National Institute for Health and Care Excellence (63), 
and the 1998 US guidelines (64). Nevertheless, the final decision for using bariatric 
surgery and the appropriate technique should always be based on the individuals and 
their needs. 
GBP surpasses other methods concerning efficacy for weight reduction. The Swedish 
Obese Subjects (SOS) Study, a prospective observational study since 1987, showed a 
mean (± SD) weight loss compared to baseline of 25±11% for GBP, 16±11% for 
vertical-banded gastroplasty, and 14±14% for banding after 10 years. After 15 years, 
the corresponding values were 27±12%, 18±11%, and 13±14%, respectively (65). The 
maximum weight loss occurred after 1 year: 38±7%, 26±9%, and 21±10%, 
respectively (66). Large comprehensive meta-analyses have confirmed the 
effectiveness and superiority of GBP with significant weight reduction and relative 
maintenance for more than 2 years (54, 67). King et al. (68) presented information on 
the percentages of patients with weight regain after bariatric surgery. The highest rate 
of weight regain occurred 1 year after reaching nadir weight and gradually continued 
thereafter, i.e. 43.6% increased ≥5 mg/kg2 5 years after reaching their nadir weight 
loss. This highlights the importance of setting realistic expectations on obesity 
resolution after surgical treatment and specifies the need of long-term 
multidisciplinary follow-up or renewed intervention. 
Furthermore, bariatric surgery and GBP have shown effectiveness for various 
comorbidity and mortality endpoints independently of the existence of T2DM. There 
are few randomized or observational studies that have studied the effects of GBP on 
study populations with both obesity and T2DM. In the SOS Study, for example, only 
7% of 2,010 patients in the GBP group had concurrent T2DM. Randomized studies 
(59, 69-71) showed significant findings with respect to comorbidities and CVD, but 
they had low power and they did not assess mortality. Analysis of the diabetes 
population in the SOS Study (72) showed a reduced incidence of myocardial 
infarction but no effect on stroke. The first meta-analysis of observational studies on 
the effects of bariatric surgery on CVD and mortality suggested a more than 50% 
reduction in mortality, myocardial infarction, and stroke compared to non-surgical 
controls; however, there was an unknown proportion of patients with diabetes (73). A 
large Swedish study, also with an unclear number of T2DM patients, was derived 
from the Scandinavian Obesity Surgery Register (SOReg): it presented outcomes 
related to various comorbidities such as T2DM, hypertension, dyslipidemia, 
depression, and sleep apnea at 1, 2, and 5 years after primary GBP (74). The most 
profound improvements occurred for T2DM and sleep apnea based on changes in 
laboratory data and medical prescription. More recently, a retrospective observational 
study, which investigated the time to occurrence of macrovascular disease after 
bariatric surgery in patients with severe obesity and T2DM, found a 40% risk 
reduction for macrovascular events but no significant effect on cerebrovascular 
disease at 5 years (75). Finally, the beneficial effect of different types of bariatric 
surgery was a 56% lower risk of microvascular disease, which was assessed through 
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hospital admission or treatment in outpatients clinics in the SOS Study (76, 77), and 
among patients who experienced T2DM remission an almost 30% lower risk in 
incidence of microvascular disease in an recent American retrospective study, which 
included 4,683 patients with T2DM followed up to 7 years (78). 
Likewise, there are few studies that have estimated mortality as it seems that a longer 
follow-up duration is required to produce clear results. Most randomized and 
observational studies are designed to investigate remission for diabetes and 
comorbidities after bariatric surgery rather than mortality. The SOS Study (65) 
showed a 24% lower risk of mortality in an unadjusted model and 29% lower risk 
after adjustment for sex, age, and risk factors. The lower risk in the surgery group was 
mainly attributed to the long-term weight loss. In a retrospective cohort study of 7,925 
matched patients who had undergone GBP, Adams et al. (79) showed a decreased risk 
of all-cause mortality (40%) and for cause-specific mortality from coronary artery 
disease (56%), diabetes (92%), and cancer (60%), over a mean follow-up of 7.1 years. 
Mortality rates by accidents or suicide were 58% higher in the GBP group. The 
existence of diabetes may play a role in mortality for patients who receive GBP. A 
stratified study of patients with or without diabetes showed a significantly lower 
mortality rate for patients with T2DM compared to those without after GBP. They 
were also less likely to die from CVD, diabetes, or respiratory disease (80). 
Irrespectively of diabetes remission, effects on other classic CVD risk factors or the 
weight loss by itself are eventually components of such evolution (81). 
 
Effects on renal disease 
The burden on renal function attributed to obesity (82, 83) or T2DM (84, 85) present 
two distinct situations that have been extensively investigated. The combination of 
both factors accelerates the risk of albuminuria, chronic kidney disease (CKD), and 
end-stage renal disease (ESRD). Hemodynamic changes related to activation of the 
sympathetic nervous and renin-angiotensin systems as well as inflammatory 
abnormalities and oxidative stress from both obesity and metabolic syndrome are 
consistent with glomerular hyperperfusion and hyperfiltration, leading to albuminuria 
and renal impairment (86-88). 
The effects of bariatric surgery, and especially of GBP, on renal function and 
development of CKD or ESRD have not been adequately investigated in a population 
with concurrent obesity and T2DM. A recently published retrospective, matched 
cohort study (89) observed T2DM patients for a median follow-up of 4.3 years after 
bariatric surgery and showed a 59% lower risk for nephropathy for the surgical group. 
Another study found resolution of albuminuria in 51% of T2DM patients over a mean 
follow-up of 61 months following bariatric surgery (90). The STAMPEDE Study (59) 
only showed a significantly lower urinary albumin-creatinine ratio in SG patients. 
Change in BMI seems to be the most reliable predictor of this renal function change, 
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particularly in the first year when patients reach their lowest postsurgical weight (91-
93). The SOS Study showed a more than 50% lower risk for albuminuria compared to 
conservative treatment; however, it failed to show a lower incidence for albuminuria 
in GBP patients, even though GBP resulted in greater weight loss (94). 
It is noteworthy that albuminuria is attenuated when weight is reduced either 
conventionally (95) or by bariatric surgery (96), meaning that patients with different 
levels of renal function could experience either an improvement or reversal of the 
progression of renal dysfunction. Shulman et al. (97) demonstrated a protective role 
by bariatric surgery against stage 4 CKD or ESRD during 18 years of monitoring, 
while Alexander et al. (98, 99) reported resolution, improvement, or stabilization of 
renal function after surgery in patients with CKD or following kidney transplantation. 
Prospective or randomized studies should more robustly evaluate the beneficial effect 
of GBP on different levels of estimated glomerular filtration rate (eGFR). 
 
Adverse events of gastric bypass 
Bariatric surgery is thus the most effective method of weight loss and regression of 
associated comorbidities; nevertheless, it is still a surgical method with complications 
and undesirable effects. Several cohort studies have reported various hospital 
readmission rates depending on bariatric technique, type of complications, and 
different duration of follow-up. Specifically for GBP, the hospital readmission rate 
has ranged from 0.6% to 11.3% within 30 days (100-104), with low mortality (0-
0.16%) (100, 105, 106), 3% major adverse events (105) but 21.4%-65.9% long-term 
outcomes (such as adhesive bowel obstruction, hernia, or psychiatric disorders) during 
longer time of observation (101). 
Adverse events of GBP have been evaluated through observational and randomized 
studies; however, this has not been sufficiently addressed in patients with concurrent 
T2DM in surgical populations. The randomized STAMPEDE Study and the Diabetes 
Surgery Study have reported the adverse events of GBP and SG and, as expected, 
were more serious than conventional management (59, 70, 107). Strictures, bowel 
obstructions/ileus, ulcers, gastrointestinal leaks, and reflux disease were the most 
frequent complications in the first year, and hypoglycemia, anemia, nutrient 
deficiencies, and depression during the entire follow-up. A Swedish observational 
study based on the Scandinavian Obesity Surgery Register (SOReg) also 
demonstrated a higher risk of internal hernia and gallstone disease, as well as a 12-
fold increased risk for additional gastrointestinal surgery after primary intervention 
(101). In addition, they highlighted the value of preoperative weight loss, which 
reduced the overall risk of postoperative complications by 13%-18%, concerning 
different types of complications (108). Finally, large US studies (104, 109, 110) have 
confirmed the aforementioned early postoperative outcomes as well as some of the 
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long-term deficiencies such as hypoglycemia and psychiatric disorders; however, the 
study populations only included low proportions of patients with T2DM. 
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2. AIMS 
The main aim of this thesis is to study the effects of GBP surgery on patients with 
obesity and T2DM. The specific aims of the individual studies are present below. 
I. The aim of the first study was to investigate the risk of cardiovascular events and 
mortality in patients with obesity and T2DM who had undergone GBP compared to 
patients with same characteristics who did not undergo surgical treatment. 
II. The scope of the second study was to thoroughly describe the changes in weight, 
glycemic control, cardiovascular risk factors, and use of medication as well as to 
assess the effect of such changes on cardiovascular disease and mortality after GBP. 
III. The objective of the third study was to identify the clinical benefits and the short- 
and long-term adverse effects of GBP in patients with obesity and T2DM compared 
with matched individuals not undergoing surgery. 
IV. The aim of the fourth study was to explore the effects of GBP on renal function in 
individuals with obesity and T2DM as well as to examine the overall safety of such 
surgery in patients with different levels of renal disease. 
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3. PATIENTS AND METHODS 
DATA SOURCES  
This thesis is based on several data sources provided by different national registries in 
Sweden. The main registries were the National Diabetes Register (NDR) and the 
SOReg. Both registries are linked to the National Board of Health and Welfare, which 
also stores data from the Swedish Inpatient Register (1997-2015). Due to the unique 
advantage of the personal identity number in Sweden, we can also link to other 
registries such as the Cause of Death Register (1996-2016), the Prescribed Drug 
Register (2005-2015), and Statistics Sweden (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Data sources linked by personal identification number  
 
We submitted our data (NDR and SOReg) and personal identity numbers to the 
National Board of Health and Welfare for the years 1996-2015 and 2007-2014, 
respectively. All the personal identity numbers were then replaced by anonymized 
serial numbers. The coded data were linked to the National Inpatient Register, 
Prescribed Drug Register, and Cause of Death Register and forwarded to Statistics 
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Sweden for linkage with the Longitudinal Integration Database for Health Insurance 
and Labour Market Studies (LISA), which provides socioeconomic data. The linked 
data were then returned to us for validation and analysis.  
 
NDR 
The National Diabetes Register was launched in Sweden by Swedish Society of 
Diabetology in 1996 to gather patient data for research purposes and the development 
of evidence-based treatment for diabetes. Physicians and diabetes nurses report data 
such as clinical information, medical measurements, and blood tests related to 
diabetes from outpatient clinics and primary care centers nationwide at least annually. 
Patients are informed about the scope of registering in the NDR as well as the 
facilitation of patient self-participation in diabetes care, so that they can provide oral 
consent or refuse inclusion in the register. Overall, more than 500,000 patients with 
diabetes are included in the NDR, covering ~90% of patients with T2DM and ~95% 
of patients with type 1 diabetes mellitus in Sweden.  
 
SOReg 
Scandinavian Obesity Surgery Register was started in May 2007 as a quality and 
research register for patients who receive bariatric surgery in Sweden. Since 2010, it 
has covered all bariatric procedures in Sweden. The aim of the register is to enhance 
the application of surgical treatment in patients with obesity, to improve surgical 
conditions and indications, and to upgrade postsurgical follow-up. All bariatric 
centers report presurgical characteristics, surgical complications, short-term 
postoperative and longitudinal effects. Recently, the follow-up time of patients in 
SOReg has been extended up to 10 years after surgery. 
 
Other Registries 
The National Inpatient Register started as National Patient Register in the 1960s and 
initially included clinical information regarding in-patients from public hospitals. It 
appeared in its present form since 1987 and includes all in-patients who are cared for 
in Swedish hospitals with complete coverage of discharge diagnoses. 
The Cause of Death Registry belongs to National Board of Health and Welfare, is 
based on death certificates, and provides statistics for time and cause of death with 
full coverage since 1961. 
The Prescribed Drug Register was established in 2005 to increase knowledge on the 
effects of prescribed medications. It records all filled prescriptions from all 
pharmacies nationwide, including information on specific drug (e.g. package size, 
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dosage instructions, date of drug dispensing), and both patient and prescriber 
characteristics with also complete coverage. 
Finally, the Statistics Sweden, which provides the LISA database, supply 
demographic, vital status, and socioeconomic data (e.g. educational levels, marital 
status, occupation, income, ethnicity) and has covered the entire Swedish population 
since 1990. 
 
PROCEDURES 
Studies I and II 
These observational, retrospective, cohort studies included adult patients (≥18 years) 
who had undergone GBP at hospitals in Sweden between January 1, 2007 and 
December 31, 2014. The studies merged data from SOReg and NDR, which provided 
a unique study population with three properties – GBP surgery, obesity, and T2DM. 
We also linked with other national registries such as the National Inpatient Register, 
the Cause of Death Register, and Statistics Sweden to study various outcomes. All 
databases have been described and validated (111, 112) (Table 1). 
We matched these patients 1:1, without replacement, to patients from NDR with 
obesity and T2DM but not undergoing GBP. The matching was based on sex, age, 
BMI, and calendar year of database entry. For this type of matching, we used different 
categories of age (0-41, 42-49, 50-55, and ≥56 years), BMI (<28, 28 to <35, 35 to 
<38, 38 to <43, and ≥43 kg/m²), and calendar time (2007-2008, 2009-2010, 2011-
2012, and 2013-2014). 
The baseline variables for studies I and II were: sex, age, BMI, type and duration of 
diabetes, HbA1c concentration, LDL- and high-density lipoprotein (HDL)-cholesterol 
concentrations, blood pressure, antidiabetic, antihyperlipidemic, and antihypertensive 
treatment, smoking status, history of myocardial infarction, congestive heart failure, 
and stroke, baseline annual income (in Swedish Krona), marital status, and 
educational level [low (up to school year 9 of compulsory comprehensive school), 
mid (years 10-12 of upper secondary school), or high (college or university)]. 
Obesity is always defined as BMI ≥30 kg/m², but we included all patients who had 
received GBP independently of BMI in our studies. T2DM was defined 
epidemiologically as onset of diabetes at ≥40 years of age and treatment by diet, 
antidiabetic drugs, insulin, or any combination thereof. Smoking was defined as 
current use of tobacco. In study I, we defined history of myocardial infarction, stroke, 
or congestive heart failure as admission to the hospital due to these diagnoses before 
baseline and using codes from the International Classification of Diseases-10 (ICD-
10) [I20-25, I61-64, and I50, respectively]. In study II, we defined remission of 
diabetes as HbA1c <6.5% (<48 mmol/mol) and physical activity as low intensity of 
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training for ≥30 min 3 times/week. The analyses of all laboratory concentrations 
(HbA1c, and LDL- and HDL-cholesterol) are quality assured nationwide and 
expressed in SI units. 
 
Table 1. Overview of the cohorts and some patients’ characteristics 
 Study I Study II Study III Study IV 
Study design Cohort Cohort Cohort Cohort 
Study period 2007-2014 2007-2014 2007-2015 2007-2015 
Exposure GBP Controls GBP Controls GBP Controls GBP Controls 
Data sources SOReg
+ NDR NDR 
SOReg
+ NDR NDR 
SOReg
+ NDR NDR 
SOReg
+ NDR NDR 
Swedish Inpatient 
Register, Cause of 
Death Register, 
LISA 
SOReg, NDR Swedish Inpatient 
Register, Cause of 
Death Register, 
LISA 
Swedish Inpatient 
Register, Cause of 
Death register, 
Prescribed Drug 
Register, LISA 
Patients (n) 6,132 6,132 6,132 6,132 5,321 5,321 5,321 5,321 
  Sex (females %) 
  Age (years) 
  BMI (Kg/m²) 
61 61 61 61 60.5 63.8 60.5 63.8 
48.5 50.5 48.5 50.5 49.0 47.1 49.0 47.1 
42.0 41.4 42.0 41.4 42.0 40.9 42.0 40.9 
Outcomes All-cause mortality, 
cardiovascular 
death, myocardial 
infarction 
Changes in BMI, 
HbA1c, LDL, 
HDL, SBP, DBP, 
blood pressure-, 
lipid- and glucose- 
lowering 
medication, 
smoking, physical 
activity 
Variety of 
diagnoses after 
admission to the 
hospitals 
Renal diagnoses 
and cardiovascular 
disease after 
admission to the 
hospitals, s-
creatinine, eGFR, 
micro- and 
macroalbuminuria 
Mean follow-up time 
(years) 3.7 3.3 3.7 3.3 4.7 4.6 4.7 4.6 
 
 
Studies III and IV 
As in the first two studies, we merged data from SOReg and NDR. However, we 
included patients (18-75 years of age) who had received GBP from January 1, 2007 
until December 31, 2013. They were followed until December 31, 2015. Relevant 
data were also derived from other registries such as the Swedish Inpatient Register, 
the Cause of Death Register, and Statistics Sweden, and, additionally for study IV, the 
Prescribed Drug Register (Table 1). 
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Patients with obesity and T2DM who had undergone GBP were matched on 
propensity score (1:1) with patients from NDR who had obesity and T2DM but did 
not undergo GBP. Matching was based on sex, age, BMI, and calendar time.  
In study III, we used ICD-10 diagnoses as recorded in the National Inpatient Register. 
In study IV, we assessed renal function using eGFR determined according to the 
Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equations. In addition, we used serum 
creatinine concentration in mmol/l and micro/macroalbuminuria with the clinical 
definition of urine albumin/creatinine ratio (>3-30 and >30 mg/mmol). Development 
of renal dysfunction included macroalbuminuria, halved eGFR value compared to 
baseline, and renal disease diagnoses as presented by ICD-10 classification. 
 
OUTCOMES 
Studies I and II 
Patients were followed from the index date (date of GBP surgery or a random date 
within 2 calendar years for controls not undergoing GBP) until the first occurrence of 
myocardial infarction or stroke, until December 31, 2012 (for data from the Inpatient 
Register), or until death or until December 31, 2014 (for data from the Cause of Death 
Register). Primarily, we were interested in fatal or non-fatal myocardial infarction, 
cardiovascular death, and all-cause mortality. Secondarily, we looked at changes in 
various risk factors in first year after baseline for those who underwent GBP. We 
assessed the changes in the control group 1 year after the index date with a range of 
90 days before and 180 days after, to avoid multiple imputations. 
In study II, we monitored patients in the terms of weight, HbA1c, lipid profile (LDL- 
and HDL-cholesterol), systolic (SBP) and diastolic blood pressure (DBP), 
pharmacological treatments, smoking, and physical activity through the whole follow-
up period (maximum 7.99 years). Furthermore, we evaluated the effect of the 
aforementioned factors on the risk of overall mortality, cardiovascular death, and 
myocardial infarction using causal mediation analysis. 
Studies III and IV 
In study III, we monitored GBP and control patients from baseline until admission to 
the hospital due to specific diagnoses related to CVD (acute myocardial infarction, 
stroke, and peripheral vascular disease), atrial fibrillation, congestive heart failure, 
and valvular disease as well as diagnoses related to diabetes mellitus or generally to 
obesity or GBP (e.g. cancer, anemia, malnutrition, alcohol abuse, psychiatric 
disorders) and all-cause mortality. We also looked at postsurgical diagnoses such as 
bleeding, complementary gastrointestinal surgery, leakage, ulcers and reflux disease, 
hernias, bowel obstruction, gall bladder disease, and pancreatitis as well as additional 
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plastic surgery. Monitoring of the two groups was conducted for up to 9 years (mean 
4.6 years). Control patients were censored at the treatment date in the surgery group. 
In study IV, patients were primarily assessed for the time to hospital admission due to 
various diagnoses (renal dysfunction, development of macroalbuminuria, or halved 
eGFR value) or censored at the end of the study (December 31, 2015) compared to 
baseline in both groups. Specifically, we were interested in diagnoses of acute and 
chronic kidney failure, hemodialysis and peritoneal dialysis, kidney transplantation, 
and diabetic nephropathy. Secondarily, we stratified our groups to different levels of 
eGFR and estimated the same outcomes. We also investigated the risk for 
development of severe renal disease or halved eGFR, CVD, congestive heart failure, 
specific mortality due to CVD or renal disease, and all-cause mortality. Finally, we 
calculated changes on several renal variables (e.g. creatinine, eGFR etc.) 1 and 2 
years after GBP.  
 
STATISTICAL ANALYSIS 
Study I 
Missing baseline data in SOReg were imputed from a multivariate normal model with 
a Monte Carlo Markov chain approach. The NDR database for controls is very large, 
making multiple imputations less feasible on the entire dataset. In addition, it would 
have been difficult to retain strong within-patient correlation for variables with a high 
missing data percentage, such as LDL- and HDL-cholesterol (42%). So, we used the 
last value carried forward (LVCF) method that preserves high within-patient 
correlations for many variables. Controls that remained without value after the LVCF 
imputation were excluded from the matching and subsequent regression analysis. 
Due to use of rather wide intervals for the matching variables, there may be more than 
one registration date that can be selected as the index date in controls. For that reason, 
we selected a random registration date for a matched control during the 2 years when 
the GBP patient received surgery. Matching of controls was undertaken without 
replacement, which means NDR patients who were selected as controls in one time 
period could not be selected as controls in later periods; however, they could be 
treated surgically later, in which case they were censored at the time of treatment. 
To compare the groups in descriptive statistics, we used absolute and mean values and 
standardized mean differences, as we only described the observed populations and 
therefore we used a measure tailored for this, independent of the sample size. P-values 
concern the population's means and the hypothesis test. We calculated p-values to 
express the significant changes in risk factors in the first year using a mixed repeated 
measure model for continuous variables, McNemar's test for discrete variables, and ² 
test for binary variables for diabetes remission. A Cox regression model with Kaplan-
Meier survival analysis was used to calculate cumulative all-cause mortality on the 
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basis of BMI changes 1 year after GBP. Log-rank test was used to estimate survival 
beyond 1 year of diabetes remission. 
Furthermore, we tried to estimate the effect of GBP treatment on outcomes by fitting 
a Cox regression model to the data, including the treatment indicator and all the 
baseline variables. As estimator, we used number of events, events rates, and hazard 
ratios (HRs) with or without adjustment for multiple baseline characteristics. Using 
Cox regression analysis, we also estimated the number of patients needed to be treated 
at 5 years of survival based on median values of all covariates. 
Finally, we also conducted a sensitivity analysis to search for unobserved 
confounding factors in relation to the outcome using the method suggested by 
Greenland (113, 114). 
Study II 
In study II, we used the same baseline characteristics as in study I. To evaluate the 
changes of variables during the 7.99-year follow-up, we constructed a linear mixed 
repeated measure model for BMI, HbA1c, LDL-cholesterol, HDL-cholesterol, SBP, 
and DBP, and a generalized mixed repeated measure model for variables such as 
smoking and use of antihypertensive or antihyperlipidemic drugs. We assumed as 
yearly mean values, measurements performed between months 6-18 as the first year, 
months 18-30 months as the second year, etc. 
In order to investigate the contribution of changes of various risk factors to our 
outcomes (all-cause mortality, cardiovascular death, and myocardial infarction), we 
used a new statistic method named causal mediation analysis (115). This method is 
formulated as a linear structural equation model and tries to identify mediators namely 
factors that eventually lie in the causal pathway between the treatment (GBP) and the 
considered outcomes. The potential mediators we examined were changes in risk 
factors such as BMI, HbA1c, SBP, and LDL- and HDL-cholesterol. 
We constructed separate Cox regression models that combined with multinomial 
logistic regression models to estimate the direct and indirect effect of the mediator to 
exposure and outcome. The direct effect is the effect of treatment without the 
corresponding effect of the mediator and indirect effect is the effect of the change in 
the mediator that is associated with the exposure but without changing the actual 
exposure. All models were adjusted for previous myocardial infarction, chronic heart 
failure, or stroke, HbA1c, SBP, DBP, smoking status, use of antihyperlipidemic, 
antihypertensive, and antidiabetic drugs, income, and educational and marital status. 
Study III 
In contrast to the previous studies, we matched groups using a propensity score for 
longitudinal exposure, which was assessed though descriptive statistics. The GBP 
patients and controls differed substantially prior to matching. It was difficult to find 
closely matching controls for all GBP patients so the matching process consequently 
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resulted in only an approximate match. We therefore included potential confounders 
not balanced after the matching process in the analysis model. The matching has the 
benefit of selecting an index date for the controls and the balance after matching was 
enough to make regression adjustment feasible. The propensity score model was set 
up as a Cox proportional hazards model with time varying covariates and exposure to 
GBP as the event of interest. The propensity score model contained covariates for sex, 
age, and BMI. 
We presented descriptive statistics with means with standard deviation (SD) for age 
and BMI, median with quartiles for income, and absolute values with percentages for 
all other variables. Incidence rates for each outcome were estimated using counts and 
person-years. In terms of time, we made comparisons between GBP patients and 
controls by constructing a Cox regression model adjusted for sex, age, BMI, and 
socioeconomic factors (income, marital status, educational level, and country of 
birth). We did not make any adjustments for multiple inferences.  
An additional Cox regression model was used to separately estimate outcomes in the 
distribution of men and women. 
Study IV 
Baseline characteristics were described by absolute frequencies or mean values with 
percentages or SDs, respectively. As in the previous studies, we used standardized 
mean differences to describe the comparability of distributions of our groups. 
We evaluated the endpoints using number of events and incidence rates per 10,000 
person-years together with exact 95% Poisson confidence intervals (CIs). The two 
groups were compared using HRs estimated with a Cox regression models adjusted 
for sex, age, BMI, eGFR, marital status, income, educational level, and country of 
birth. First- and second-year postoperative clinical characteristics are described using 
descriptive statistics and compared between groups using ANCOVA and logistic 
regression models including covariates at baseline. 
 
ETHICAL CONSIDERATIONS 
The overall aim of this thesis was to gain knowledge on patients who undergo GBP 
and, at the same time, are diagnosed with T2DM and obesity. Such knowledge can be 
best accessed using organized databases which contain considerable clinical 
information on patients with specific characteristics of the diseases we are interested 
in. All four studies used data from the aforementioned databases while adhering to the 
conditions that such research procedure require according to the rules and processes 
dictated by the Swedish health system. The linkage of data from various registries to 
the NDR was performed by the National Board of Health and Welfare, coded, and 
then delivered as anonymous data to the researchers. 
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Ethical aspects of register research primarily concern privacy and data security. 
Register research generally entails minimal risk for patients, risks that can, in 
principle, be eliminated by adequate security and coding/de-identification of data. In 
the registries which we used, the patients have largely been informed about possible 
participation in different studies at the time of first visiting outpatient or primary care 
clinics. At that time, they have the right to refrain from participation in research 
projects. The NDR and SOReg are large research institutions that preserve the privacy 
and integrity of participants through data de-identification and group-level data 
analysis without nationality discrepancy or arbitration. 
The ethics application for our studies approved by the Regional Ethical Review Board 
in Gothenburg. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20
21 
 
4. RESULTS 
 
Mortality and cardiovascular risk in patients with obesity, diabetes mellitus, and 
GBP 
This study compared 6,132 patients with obesity and diabetes who had undergone 
GBP with equal number of patients with obesity and diabetes who did not undergo 
such treatment between January 1, 2007 to December 31, 2014. The median follow-
up for the groups was 3.5 years (maximum 7.99 years). At baseline (shown in the 
attached paper), there were some minor differences between the groups in several 
characteristics. Matching only provided similarity between the groups in terms of sex, 
duration of diabetes, and HbA1c and LDL-cholesterol concentrations. 
Analysis revealed significant differences in all-cause mortality, cardiovascular death, 
and myocardial infarction between the groups (Figure 2). Fewer patients died overall 
in the GBP group compared to controls (82 vs 288 patients), with a risk reduction of 
58% as shown by Kaplan-Meier curves. There were 13 cardiovascular deaths in the 
GBP group compared to 67 in the control group, with a risk reduction of 59%. The 
HR for myocardial infarction in patients was 0.51 (95% CI, 0.29-0.91). Similar risk 
reductions were observed when we excluded patients with prior CVD or congestive 
heart failure. The 2-year and 5-year absolute risk of all-cause mortality was 0.4% 
(95% CI, 0.3%-0.6%) and 1.8% (95% CI, 1.5%-2.2%) in the GBP group, 
respectively, compared to 1.8% (95% CI, 1.4%-2.4%) and 5.8 % (95% CI, 5.0%-
6.8%), respectively, in matched controls. Based on the 5-year absolute risk for patient 
with median values of various covariates, we calculated the number of patients 
needed to be treated was 76.6. 
 
21
22 
 
 
Figure 2. Cumulative incidences of mortality (A), cardiovascular mortality (B), and fatal or 
non-fatal myocardial infarction (C). From Eliasson et al., Lancet Diabetes Endocrinol. 
2015;3(11):847–54. Reprinted with permission.  
 
There were significant differences in all parameters (BMI, HbA1c, LDL- and HDL-
cholesterol, SBP, DBP, and antidiabetic and antihypertensive drug use) apart from 
antihyperlipidemic drug use and smoking. Twenty-three percent of GBP patients had 
HbA1c <6.5% (<48 mmol/mol) at baseline, which increased to 52% at 1 year after 
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surgery. Corresponding values were 25% and 29% in controls, with the between 
group change being significant (p<0.0001). 
The Cox model evaluating cumulative all-cause mortality in relation to different BMI 
changes in the first postsurgical year. This showed no significant mortality reduction 
in patients who did not have weight reduction or had the lowest BMI reduction (<2 
kg/m²). There was mortality reduction among those with BMI reductions of 2-9 kg/m² 
(p=0.0027) or >9 kg/m² (p=0.0005). The risk of mortality during diabetes remission in 
the first year showed a risk reduction of 38% (p=0.0066) compared to the patients not 
in remission. 
In additional analysis, a Cox regression model that included all the baseline factors 
(presented in the supplementary appendix of the original study) found that age, 
previous heart failure, and smoking were independent predictors for all-cause 
mortality. GBP, being female, and being married were protective factors. Age, 
previous myocardial infarction, and heart failure increased cardiovascular death, 
while GBP and being female were protective factors. The risk of myocardial 
infarction also increased with high SBP values. 
Finally, to detect potentially unobserved confounders, we conducted sensitivity 
analysis which arbitrarily tested for the existence/prevalence of an unknown factor 
that might influence mortality risk. No additional significant effect was found. 
 
Changes in risk factors after GBP and their contribution to mortality reduction 
In continuation from the previous study, we used the same cohort to look deeper at the 
changes of baseline characteristics and risk factors after GBP and over a shorter 
observation period. The maximum time for which we presented data was up to 6 
years, with a median of 3.7 years for GBP patients and 3.1 years for controls. In 
contrast to the previous study, we decided to present data for this duration of follow-
up because of relatively stable mean values and narrow CIs for at least 6 years. 
We used a more advanced model for repeated measurements to investigate the 
changes of various risk factors from baseline. BMI reached its nadir in the second 
year in the GBP group at 31.9 (95% CI, 31.7-32.1) kg/m² and remained significantly 
lower than matched controls during the 6-year follow-up. The lowest value for HbA1c 
was seen in the first year 6.32% (95% CI, 6.27%-6.38%) and also remained 
significantly lower throughout the whole follow-up period. Compared to the results of 
the previous study, we found different remission rates for diabetes (36.8% and 9.3% 
in GBP patients and controls, respectively, in the first year), whereas a different 
mixed repeated measure model was used for analysis.  
Lowering of LDL-cholesterol was significant through the first 3 years in the GBP 
group, which was independent of the higher consumption of lipid-lowering drugs in 
the control group. HDL-cholesterol increased gradually and plateaued until the end of 
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observation in the GBP group. SBP showed the same pattern of change as LDL-
cholesterol in the GBP group, but was maintained significantly lower than controls for 
4 years. DBP was also reduced in the GBP group, but for a shorter duration despite 
the more prevalent use of antihypertensive agents in the control group.  
The proportion of smokers was significantly lowered in the first 2 years and physical 
activity was increased for 5 years in GBP group. 
Causal mediation analysis, a new statistical method, was undertaken to try and find an 
explanation for the reduction in all-cause mortality, cardiovascular death, and 
incidence of myocardial infarction after GBP. In this model, we examined the indirect 
and direct effect of factors (e.g. BMI, HbA1c, SBP, HDL- and LDL-cholesterol) if we 
assume that they work or do not work as mediators in the relation between GBP and 
outcome (Table 2). We found that the lower all-cause mortality and cardiovascular 
death were significantly mediated through the BMI reduction (an indirect effect). 
There was no significant effect on myocardial infarction. In contrast, the direct effect 
of the GBP procedure that was not mediated through the BMI reduction provided a 
significantly higher risk of all-cause mortality and lower risk of myocardial infarction. 
Changes in the other factors did not have any significant indirect effect on outcome. 
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Table 2. Causal mediation results for patients treated with gastric bypass 
 
From Liakopoulos et al., BMJ Open Diabetes Res Care. 2017;5(1):e000386. Reprinted with 
permission.  
 
 
Clinical benefits and postoperative short- and long-term effects of GBP in 
patients with obesity and T2DM 
To study both the advantages and disadvantages of GBP surgery in patients with 
obesity and T2DM, we merged data from SOReg and NDR as in previous studies but 
we included surgery patients from January 1, 2007 until December 31, 2013. They 
were followed until December 31, 2015. Median follow-up time was 4.6 years 
(maximum 9 years) and the number of patients in each group was 5,321.  
With respect to the clinical benefits of GBP, there were lower incidences of all-cause 
mortality, CVD, acute myocardial infarction, and congestive heart failure, as partially 
shown in the first study. Moreover, hospitalization for diagnoses related to diabetes 
such as hyperglycemia, amputation, and kidney disease was characteristically less 
frequent after GBP. Cancer diagnosis also appeared less frequent in the GBP group. 
Events rates for hospital admission due to anemia (2- fold higher), malnutrition (3-
fold higher), alcohol abuse (3-fold higher), and psychiatric disorders (HR 1.33; 95% 
CI, 1.13-1.58) differed significantly compared to the matched controls. As expected, 
there was a higher risk of short-term postoperative adverse events among the patients 
who underwent GBP surgery. Postoperative effects potentially occurring after GBP 
25
 
 
 
 
 
 
Causal mediation with Cox regression for patients treated with gastric bypass 
 Overall mortality Cardiovascular death Myocardial infarction 
Variable (effect) HR 95% CI P value HR 95% CI P value HR 95% CI P value 
BMI (direct) 1.956 1.002-3.821 0.0494 1.737 0.594-5.082 0.3133 0.317 0.133-0.756 0.0096 
(indirect) 0.384 0.179-0.821 0.0136 0.145 0.028-0.750 0.0213 1.068 0.377-3.030 0.9014 
HbA1c (direct) 0.329 0.193-0.560 <0.0001 0.292 0.062-1.375 0.1195 0.488 0.230-1.037 0.0620 
(indirect) 1.361 0.930-1.993 0.1123 0.988 0.350-2.789 0.9821 0.841 0.468-1.513 0.5641 
SBP (direct) 0.611 0.398-0.938 0.0241 0.263 0.051-1.358 0.1109 0.531 0.247-1.143 0.1054 
(indirect) 0.948 0.672-1.339 0.7631 0.776 0.296-2.036 0.6069 0.889 0.537-1.472 0.6479 
HDL (direct) 0.493 0.280-0.868 0.0143 0.304 0.050-1.839 0.1948 0.521 0.222-1.227 0.1358 
(indirect) 1.024 0.649-1.616 0.9197 0.748 0.236-2.370 0.6222 0.681 0.383-1.211 0.1910 
LDL (direct) 0.567 0.346-0.930 0.0245 0.187 0.026-1.326 0.0935 0.347 0.156-0.772 0.0095 
(indirect) 1.023 0.703-1.491 0.9041 1.664 0.553-5.010 0.3648  1 .079  0 .592-1 .967  0 8038.
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were abdominal pain, bowel obstruction, gallstones, gallbladder disease, pancreatitis, 
gastrointestinal ulcers, reflux, hernia, gastrointestinal leakage, wound complications, 
and bleeding. Additional gastrointestinal intervention after GBP occurred in 17.6% of 
cases and reconstructive plastic surgery was also more frequent. 
When the sexes were considered separately in a different model with the same 
adjustments, we noted that men had significantly higher hospitalization risks for fatal 
CVD, atrial fibrillation, congestive heart failure, and additional gastrointestinal 
surgery, and women for psychiatric disorders after GBP. 
 
GBP surgery and changes in renal function in patients with obesity and T2DM 
Effects of bariatric surgery on renal function have partially been investigated, but 
there is no clear information on the effects of GBP in patients with obesity and 
T2DM. With this aim, we used same cohort as in study III to determine the risk of 
hospitalization due to renal disease and to investigate the changes in renal function 
after such intervention. 
The risk of hospitalization for acute (HR 0.57; 95% CI, 0.36-0.90) or chronic kidney 
disease (HR 0.45; 95% CI, 0.30-0.67) for patients who had undergone GBP was lower 
compared to matched controls. The same was found for diabetic nephropathy (HR 
0.22; 95% CI, 0.10-0.47), which is a separate diagnosis in the ICD-10 classification. 
Six patients were admitted to hospital with a diagnosis of hemodialysis or peritoneal 
dialysis compared to 27 patients in the control group but there was no difference in 
patients requiring kidney transplantation. Combination of kidney diagnoses, which 
included common outcomes of severe renal disease, also showed lower risk (HR 0.50; 
95% CI, 0.37-0.68) in GBP group. 
The lower mortality risk has already been presented. For this reason, we extended 
analysis by using a new outcome, which combined mortality and kidney failure. We 
concentrated on death events that happened within 28 days after renal diagnosis, as 
we think that should better describe the mortality associated with renal disease. We 
found an HR of 0.48 (95% CI, 0.22-1.04). Death related to CVD was likewise lower 
(HR 0.36; 95% CI, 0.22-0.58) in GBP group (Table 3). 
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Table 3. Number of events, incidence rates per 10,000 person-years, and adjusted HRs  
Endpoint Gastric bypass 
(n=5321) 
Control 
(n=5321) 
Hazard ratio 
with 95% CI 
p-value 
Half eGFR (MDRD)  
(ml/min/1.73 m²) 
51 (20.43) 120 (49.00) 0.63 [0.45, 0.89] 0.0076 
Half eGFR (CKD-EPI) 
(ml/min/1.73 m²) 
40 (16.02) 105 (42.86) 0.58 [0.40, 0.85] 0.0046 
Macroalbuminuria 305 (127.22) 575 (252.33) 0.55 [0.47, 0.65] <0.0001 
Acute kidney failure 52 (20.85) 74 (30.14) 0.57 [0.36, 0.90] 0.0147 
Chronic kidney disease 52 (20.84) 114 (46.62) 0.45 [0.30, 0.67] 0.0001 
Diabetic nephropathy 17 (6.79) 53 (21.59) 0.22 [0.10, 0.47] <0.0001 
Severe renal disease 98 (39.49) 187 (76.87) 0.50 [0.37, 0.68] <0.0001 
Severe renal disease or half 
eGFR value (MDRD) 
135 (54.57) 260 (107.39) 0.56 [0.44, 0.71] <0.0001 
Severe renal disease or half 
eGFR value (CKD-EPI) 
124 (50.09) 245 (101.14) 0.54 [0.42, 0.70] <0.0001 
Hemodialysis or peritoneal 
dialysis 
6 (2.39) 27 (10.97) 0.25 [0.08, 0.72] 0.0104 
Kidney transplantation 6 (2.39) 6 (2.43) 0.62 [0.12, 3.39] 0.5854 
Fatal kidney disease 12 (4.79) 32 (12.97) 0.48 [0.22, 1.04] 0.0636 
Cardiovascular disease 291 (120.10) 346 (145.29) 0.74 [0.61, 0.89] 0.0015 
Non-fatal cardiovascular disease 286 (117.91) 333 (139.69) 0.82 [0.70, 0.97] 0.0184 
Congestive heart failure 86 (34.56) 233 (96.40) 0.33 [0.24, 0.46] <0.0001 
Fatal cardiovascular disease 31 (12.36) 93 (37.69) 0.36 [0.22, 0.58] <0.0001 
All-cause mortality 183 (72.90) 351 (142.06) 0.58 [0.47, 0.72] <0.0001 
 
 
Apart from the clinical outcomes, there were beneficial effects on laboratory findings 
during the follow-up period. We found risk reductions of 45% for macroalbuminuria, 
37% for halved eGFR calculated with the MDRD equation, and 42% for eGFR 
calculated with the CKD-EPI equation (Figure 3). 
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Figure 3 Cumulative incidences during the 9 years follow-up 
When we looked more closely at the change in macroalbuminuria during the first 2 
years of follow-up, we only found significantly lower values compared to baseline in 
the second year. However, creatinine and eGFR changed inversely from the first year 
of observation. HbA1c followed the pattern of BMI change from baseline and was 
significantly different compared to the control group. 
We also analyzed the same outcomes according to different levels of renal function, 
i.e. stratification according to different eGFR levels. The adjusted model showed that, 
in patients with normal renal function (eGFR >90 ml/min/1.73 m²), there was a lower 
risk in the GBP group for acute kidney failure, diabetic nephropathy, severe renal 
disease, macroalbuminuria, CVD and CVD mortality, congestive heart failure, and 
all-cause mortality. For intermediate eGFR levels (30-60 ml/min/1.73 m²), there was a 
lower risk in the GBP group for chronic kidney disease, partially for a composite of 
severe renal disease or halved eGFR and CVD events, and also partially for heart 
failure and all-cause mortality. All the results from these categories should be 
interpreted cautiously because of the low number of the subjects and the broad CIs. 
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For low eGFR levels (<30 ml/min/1.73 m²) who underwent GBP regardless of the 
relative contraindication for bariatric surgery, there was a lower risk for 
hospitalization due to chronic kidney disease compared to the controls (HR 0.28; 95% 
CI, 0.16-0.47). Lower risks were also noted for diabetic nephropathy, severe renal 
disease, hemodialysis or peritoneal dialysis, fatal kidney disease and CVD, 
macroalbuminuria, halved eGFR value, hospitalization of congestive heart failure, and 
all-cause mortality. Incidence rates for CVD were similar in both groups with many 
patients suffered. 
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5. DISCUSSION 
 
Gastric bypass: in the service of reducing mortality and cardiovascular risk 
Analysis of nationwide Swedish data on patients with obesity and diabetes who had 
undergone GBP showed significant reductions in all-cause mortality, cardiovascular 
death, and myocardial infarction compared to matched controls with obesity and 
diabetes who did not undergo surgery. Most previous studies on bariatric surgery have 
generally focused on populations with a small proportion of patients with diabetes. 
Randomized studies published in the last 5 years generally have a short follow-up, 
which does not allow the derivation of answers related to mortality. 
Our findings are consistent with studies that have recently started to address questions 
related to mortality by examining longer follow-up (80). Previous reports in the 
literature, such as the SOS Study (65) and the Look AHEAD Study (48), have 
suggested benefits with respect to mortality and cardiovascular events that appeared 
after 4-5 years of follow-up. Specifically, the SOS Study demonstrated a 24% risk 
reduction of all-cause mortality, 53% for cardiovascular death (116), and 44% for 
myocardial infarction (72) during a follow-up period up to 16 years. However, it did 
not clarify the mechanism of bariatric surgery with respect to favoring improved 
survival. The intensive lifestyle intervention in the Look AHEAD Study contributed 
to the reduction of cardiovascular morbidity and mortality, in those who lost more 
than 10% of their bodyweight in the first year of study. The ADAPT Trial, which 
randomized patients to an 18-month weight loss intervention through dietary 
counseling and lifestyle modification, found a 50% risk reduction for overall mortality 
over a mean 8-year follow-up (117). This supports the hypothesis that long-term 
weight reduction is the factor related to lower all-cause mortality regardless of the 
method by which weight is reduced. 
Apart from weight reduction as a comprehensive factor for risk reduction, a 
constellation of factors, e.g. anatomical, physiological, hormonal, behavioral, may 
potentially cooperate (118, 119). GBP in patients with diabetes contributes to changes 
in incretin secretion, especially for GLP-1, which remains a focus of research. Higher 
levels of GLP-1 after weight reduction, especially after bariatric surgery, has been 
suggested to play a key role in increased insulin secretion by ameliorating of impaired 
-cell function (120). Improved glucose tolerance is noted (mostly due to a negative 
energy balance resulting from weight loss), which improves first hepatic and later 
peripheral insulin sensitivity in combination with increased postprandial insulin 
secretion elicited particularly by exaggerated GLP-1 responses (121). Other incretins 
such as glucose-dependent insulinotropic polypeptide that decreases after GBP 
contribute most to lipolysis rather to increasing insulin secretion (122). Existing 
assays do not provide robust conclusions about precise mechanisms of action.  
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Some of the beneficial effects on glucose concentration and HbA1c after GBP maybe 
attributed to the changes of GLP-1 and other hormones. At the same time, we found a 
clear reduction in the use of antidiabetic medications and in the proportion of patients 
with diabetes remission (52% at 1-year postsurgically). Randomized studies have also 
noted the effects of GBP in T2DM control on improved remission rates, although they 
used different criteria for remission, type of surgery, and duration of diabetes 
presurgically (59, 69, 70). It is remarkable that patients with better glycemic control 
have higher use of antihypertensive and antihyperlipidemic drugs showing the 
improved care and frequent post-operative control. Of course, we should not overlook 
the role of changes in diet and lifestyle and their contribution to impacting 
cardiovascular morbidity and mortality in patients with T2DM (123). 
Our study demonstrated a lower mortality rate as well as a lower rate of 
cardiovascular death and fatal or non-fatal myocardial infarction, despite the low 
prevalence of cardiovascular events. A possible explanation might be the fact that 
patients died outside of hospitals, which means they are not always recorded in the 
Inpatient Register but only in the Cause of Death Register. This is likely to affect the 
accuracy of diagnoses of death as it does not take into account the medical 
background of patients. However, the results remain unaltered when patients with 
previous cardiovascular history are excluded from the analysis.  
 
Changes in risk factors attributed to GBP in patients with diabetes 
Further to the previous study, we followed the course of several risk factors that have 
been traditionally associated with cardiovascular disease after GBP in patients with 
obesity and diabetes, and we compared them to patients who received conventional 
non-surgical treatment. We found significant improvements in BMI, HbA1c, and 
HDL-cholesterol during the entire follow-up period, and a partial improvement in 
LDL-cholesterol, blood pressure, smoking use, and physical activity. The more 
advanced model used for repeated measurements, compared to the simple model in 
previous study, allowed us to demonstrate significantly lower consumption of 
medications in the surgery group. As in the first study, the use of antihyperlipidemic 
agents was increased compared to baseline in the GBP group. 
Almost all studies of bariatric surgery and GBP have shown decreases in BMI over 
time. Observational studies such as the SOS Study, the Utah Study, or that of 
Courcoulas and colleagues (66, 124, 125) as well as randomized studies (59, 69, 70, 
126-128) have shown a mean weight reduction ranging from 16.1% to 33.3% over 
different observation or randomization periods from 2 to 10 years. All these studies 
report clear weight loss from the first postoperative year of observation, as we also 
reported, which was highest in the second year and maintained during the entire 
follow-up period. The same pattern of change was followed by HbA1c, but we could 
not identify this as clear factor on the effect on all-cause mortality according to our 
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causal mediation analysis. The effect of the GBP procedure is only mediated through 
weight reduction and not through the changes in HbA1c, SBP, and LDL- and HDL-
cholesterol. Changes in these traditional risk factors contribute to lower risk of 
atherosclerotic vascular and cardiovascular disease, however they do not fully explain 
the reduction in incident CVD, and the mechanisms behind this effect remains 
elusive, as suggested previously (129-131). 
The diabetes remission rate in the first postoperative year was lower (36.8%) in study 
II than study I (52%). This is due to the different models used for repeated 
measurements taking into account the parameter of time. Notably, we had comparable 
remission rates as reported in randomized studies (69, 126), meta-analysis (132), and 
reviews (133). It is now generally accepted that GBP and bariatric surgery are 
effective methods for treating diabetes in patients that have an indication for surgical 
treatment. The weight loss in combination with diabetes remission as well as the 
possible improvements in other metabolic parameters, blood pressure, and lipid 
profile actually translates into reduced macro- and microvascular events. 
The insulin-resistant metabolic environment that accompanies excess body fat is 
actually the basis of hyperlipidemia noted in individuals with obesity. The delayed 
metabolism of very low density lipoproteins implies high levels of triglycerides and 
LDL-cholesterol, and increased activity of hepatic lipids facilitates HDL-cholesterol 
clearance (23, 134). The effect of GBP on LDL-cholesterol in our study was limited 
to the first 3 years of observation, while HDL-cholesterol increased significantly 
during the entire follow-up. This is in line with studies such as the Look AHEAD 
Study (45, 46), which investigated cardiovascular risk factors and moderate weight 
loss, but differed compared to the Utah Study (135), which investigated severe obesity 
and higher proportions of weight reduction. Possible explanations might be the higher 
consumption of antihyperlipidemics compared to baseline and the higher use in 
controls compared to the treatment group, as well as a healthier lifestyle after the 
surgery. 
Both SBP and DBP follow the course of LDL-cholesterol change despite the lower 
use of antihypertensive medication compared to baseline and the control group. The 
issue of higher consumption of antihypertensives by the controls is a confounding 
factor. The effects of bypass surgery on the prevalence of hypertension are variable, 
procedure-related, and time-dependent. During the active weight loss phase, blood 
pressure decreases and antihypertensive drugs are often discontinued (136). After 
weight stabilization, the results are less clear with more factors which could play a 
significant role such as age, number of preoperative antihypertensive medications 
including diuretics (137), and preoperative duration of hypertension. A meta-analysis 
of 22 studies using a variety of bariatric surgical approaches found the mean relative 
risk of hypertension was reduced by 46% between 24 and 50 months and 
hypertension risk reached a nadir when BMI was also reached its lowest level with a 
10 mg/m2 reduction (55). The SOS Study did not show a significant reduction in 
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hypertension compared to baseline and there was an increase from the sixth year of 
follow-up (66). 
The Framingham Heart Study (138) as well as other studies (139) have established the 
role of smoking cessation in reducing cardiovascular risk and mortality. We showed a 
lower incidence of smokers than in controls, but we could not draw any conclusions 
on the effect with respect to survival. The same occurred for physical activity, which 
was significantly higher during almost the entire follow-up; however, this was not 
included in the mediation analysis model to examine whether there was a mediated 
effect on mortality and other outcomes. There may be other factors that we did not 
analyze which may play a key role in lowering mortality and cardiovascular risk in 
patients who undergo GBP. It is also very likely that the factors we did examine 
jointly contribute to enhancing outcome according to the hypothesis of 
multifactoriality. 
 
Beneficial effects and adverse events of GBP in patients with T2DM 
In this comprehensive observational retrospective study, we presented some of the 
previously shown beneficial effects of GBP as well as the spectrum of both short- and 
long-term adverse events from such treatment in patients with obesity and T2DM. 
Specifically, we investigated hospitalization due to various diagnoses potentially 
related to GBP. 
Admission rates due to cardiovascular diagnoses such as CVD, fatal CVD, fatal 
coronary heart disease, acute myocardial infarction, and congestive heart failure were 
significantly lower in the GBP group during the entire follow-up. Cardiovascular risk 
in combination with lower all-cause mortality has already been discussed previously 
on the basis of our previous work (140, 141). The incidence of congestive heart 
failure after GBP has not been adequately studied. There is a Swedish register study 
that shows similar results for postsurgical heart failure (HR 0.54; 95% CI, 0.36-0.82) 
in an unknown number of patients with T2DM over a median duration of 4.1 years 
(142). We also believe that the lower cardiovascular risk with lower incidence of 
myocardial infarction in addition to improvements on diabetes and hypertension could 
provide a convincing answer to this result. 
The results show that hospitalization due to diagnoses related to diabetes decreases 
after GBP. Incidences of hyperglycemia, kidney disease, and amputation mainly due 
to diabetic foot are most beneficially influenced by improved glycemic control. 
Inpatient care for hypoglycemia after GBP was not significantly different compared to 
controls: this might depend on the existence of diabetes and antidiabetic treatment in 
both groups, thus factors which are not taken into account by studies listing the side 
effects of gastric bypass. Otherwise, accelerated emptying of nutrients from the 
stomach to the intestine, increased insulin secretion because of increased incretin 
hormones, increased islet functional activity, and increased insulin sensitivity after 
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GBP are used to explain the slightly higher prevalence of hypoglycemia (143). The 
exact prevalence for such diagnoses varies (144, 145). 
Renal disease after GBP is the most frequently studied among microvascular diseases 
(94, 96, 146). We showed a 42% lower relative risk of hospitalization due to severe 
renal disease. The STAMPEDE Trial showed a lower albumin/creatinine ratio in the 
surgery group (59) and, in a recent study of microvascular outcomes, surgical 
treatment in patients with stage 3 and 4 CKD had significant improvements in eGFR, 
especially among those who underwent GBP (146). These findings could be applied 
in such patients with higher burden of disease and impaired renal function, as 
improvements on glycemic and blood pressure control could as well contribute to 
lower consumption of antidiabetic and antihypertensive drugs, decreasing the 
progression rate of renal dysfunction. 
Abdominal pain, gastrointestinal leakage, bleeding, bowel obstruction, 
gastrointestinal ulcers, and reflux are often reported as complications shortly after 
GBP. These adverse effects mainly occur in the first 30 days postsurgically, as seen in 
other studies (102, 147). Increased incidences of hernia, gallbladder disease, and 
pancreatitis occur in the first year of follow-up. An almost 3-times higher risk for 
gallbladder disease has been observed in parallel with a 3.5-times higher risk of 
cholecystectomy presented in a large cholecystectomy study (148). Weight reduction 
in combination with defective gallbladder emptying postoperatively and change in 
production of bile components have been suggested as possible mechanisms (149). It 
is remarkable that additional gastrointestinal surgical treatment after GBP is increased 
12 fold (101). In our study, 17.6% of patients in the GBP cohort underwent 
complementary surgery due to various complications from the primary operation. 
Incidences of rehospitalization due to postsurgical diagnoses are comparable with 
other studies that had not included a large proportion of patients with diabetes, 
implying that diabetes per se does not raise the complication rate (150). Finally, 
except for the slightly higher incidence of additional surgical procedures in men, there 
were no major differences between men and women with respect to complication risk. 
Long-term adverse events consisted of diagnoses such as malnutrition, anemia, 
psychiatric disorders, alcohol abuse, and cancer. We studied diagnoses after 
hospitalization and we may have therefore missed diagnoses that are usually 
registered during primary care. We found 3- and 2-fold higher incidences of 
hospitalization for malnutrition and anemia, respectively, compared to controls 
despite the possible underestimation of these diagnoses. Prior to GBP, the patient 
must be made aware of the increased need for post-operative treatment. It is also, 
therefore, important to adhere to the established indications for GBP. It is also well 
known that GBP is associated with increased incidences of iron, vitamin B12, folate, 
calcium, vitamin D, and, less frequently, vitamin A deficiencies (151). Iron and folate 
deficiencies are the factors most correlated with anemia, although long-term vitamin 
B12 deficiency should not be overlooked (152). Anatomical and physiological changes 
34
35 
 
alone should not be considered as solely responsible for the occurrence of nutritional 
deficiencies: postoperative non-compliance by patients should also be considered. 
Hospital admission due to psychiatric disorders was observed 33% more often after 
GBP overall and, in particular, 51% more often in women. We have not yet specified 
the main diagnoses among the psychiatric disorders, but previous studies were mostly 
focused on depression, suicidal tendency, and alcohol/substance addiction. 
Characteristically, they have shown that depression progresses along with suicidal 
attempts, primarily if there is a diagnosis of self-harm or depression in the patient's 
previous medical history (153, 154). The SOS Study demonstrated initial 
improvements in depression and health-related quality of life that gradually 
deteriorated as follow-up lengthened; however, after 10 years, there was still an 
improvement compared to baseline values (155). Neuroendocrine alterations, 
exacerbations of depression and anxiety, nutritional deficiencies, or eating disorders 
might contribute to suicide ideation. In addition, the higher incidence of alcohol abuse 
might be related to the physiological alterations induced by GBP. Patients undergoing 
GBP surgery seem to be more prone to developing alcohol abuse disorders, which is 
possibly related to the altered uptake and metabolism of alcohol seen after GBP (156, 
157). 
Cancer incidence and death rates due to all -type of cancers are correlated with 
increasing BMI (158). This association is accentuated when obesity is combined with 
diabetes (6% of cancer cases worldwide) (34). Our study showed a 22% lower risk of 
hospitalization due to all -types of cancer after GBP in patients with T2DM. This 
effect was not similar in men and women, as previously observed in SOS, suggesting 
differences in body composition and hormonal alterations as plausible explanations 
(159). A recent systematic review showed unclear results regarding cancer-related 
outcomes of randomized studies, but significantly reduced risk in non-randomized 
and cohort studies (160). The heterogeneity of the included studies, as well as 
methodological differences, did however not allow firm conclusions.  
With our study, we tried to thoroughly demonstrate the pros and cons of GBP surgery. 
Crucially, there may be a need for more robust criteria along, possibly with scoring 
systems or algorithms that could be applied by multidisciplinary teams on assessing 
indication for bariatric surgery in individual patients. The indications of bariatric 
surgery have been repeatedly updated by the National Institute of Health since 1991; 
however, the risks of such treatment are still significant and affect the final outcome. 
 
Renal disease and renal function after gastric bypass in patients with T2DM 
We also demonstrated a lower incidence in various categories of renal disease and 
adverse renal parameters after GBP in patients with obesity and T2DM compared to 
controls. We again report the beneficial effect of GBP on cardiovascular outcomes 
and mortality in patients with relatively normal renal function, supporting the validity 
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of our findings in our previous studies. The positive effects seem slightly weaker in 
patients with intermediate eGFR values and stronger in patients with eGFR lower than 
30 ml/min/1.73 m². 
The relationship of obesity and CKD, independently of diabetes and hypertension, has 
been well documented (82, 161). A review and meta-analysis from Italy (162) 
revealed that obesity is a significant predictor for CKD by increasing the risk of new-
onset low eGFR by 28% and albuminuria by 51%. Hemodynamic factors (increased 
renal blood flow and hypertension) and metabolic changes (e.g. hyperleptinemia, 
increased free fatty acids, hyperinsulinemia, insulin resistance), which cause 
sympathetic nerve stimulation, increased vascular tone, endothelial dysfunction, and 
renal sodium retention have been proposed in the mechanism of hyperfiltration, 
albuminuria, and glomerulosclerosis (163). The relationship between T2DM and renal 
disease has also been well studied in the United Kingdom Prospective Diabetes Study 
(UKPDS) (164), which showed an almost 40% incidence of albuminuria and 30% for 
renal disease over a 15-year exposure to high blood glucose (85). Both conditions 
affect renal function, which in turn can be affected by weight reduction (91, 94, 141). 
Positive changes in fat distribution, insulin secretion and resistance, glucose, HDL-
cholesterol, and triglycerides can predict additional improvement in albuminuria and 
renal function (94). 
We believe that the aforementioned mechanisms are reasonable for our findings, as 
almost all the examined renal diagnoses and laboratory findings after GBP had lower 
incidences except for the diagnosis of kidney transplantation, which was equally 
balanced between the groups. However, the low number of events for kidney 
transplantation does not allow for a reliable conclusion. It is possible that GBP could 
act as bridge to renal transplantation; thus, patients who have ESRD might undergo 
bariatric surgery to improve comorbidities and, concomitantly, create better access to 
renal transplantation (165). 
The most beneficial effects of GBP seem to occur in patients with eGFR>60 and <30 
ml/min/1.73 m², as these groups included the highest proportions of patients who 
underwent surgery, providing effect sizes with power to interpret. On the contrary, we 
observed that patients who received bariatric surgery in intermediate eGFRs are fewer 
and have various HRs even though renal function differs little between those eGFR 
groups. It was impressive that the group with the lowest eGFR,  where beneficial 
results are shown for various endpoints, even though there is a relative 
contraindication to bariatric surgery in patients with such eGFR levels. Actually, this 
is not clear from European or American guidelines, but from the uncertainty of 
anesthesiologists to proceed with anesthesia (166, 167). Unfortunately, there are few 
studies that have estimated the effect of GBP or bariatric surgery in patients with 
impaired renal function. Imam et al. (146) assessed eGFR changes in patients with 
stage 3-4 CKD compared to patients not having bariatric surgery during a 3-year 
period, and Afshinia et al. (95) showed that weight loss in overweight and patients 
with obesity led to significant decrease of albuminuria regardless of method of weight 
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loss. The SOS Study also determined the incidence of stage 4-5 CKD/ESRD (reduced 
by 65% in the surgery group) as an endpoint in patients that had normal renal function 
at the baseline and underwent bariatric surgery showing protection against ESRD 
(97). 
 
Strengths and limitations of the studies 
This thesis is based on four observational studies with data derived from quality 
nationwide databases (NDR and SOReg) using unselected inclusion of all patients 
with T2DM who undergone GBP in Sweden. This is a major strength of our studies, 
as both registries have a high rate of coverage for such patients – almost 98% of 
patients who receive bariatric surgery are recorded in the register. This high 
participation rate provides high power and external validity, especially for countries 
that also follow same criteria and the surgical contraindications endorsed by the 
European and International Association for the Study of Obesity in 2013. The quality 
of the registries, which is strengthened by previous studies (112, 168) and by 
validation with medical records (111), increases the internal quality of data, allowing 
safer conclusions and results that are similar to randomized studies. 
The amount of missing data at baseline, which is handled by different models in 
SOReg and NDR, and the gradual decreased recording of data postoperatively were 
the main limitations of our studies. Baseline data which are not completed by the 
imputation procedure remained out of the regression models. To handle the missing 
follow-up data implies successful input into mixed repeated measures models, 
providing adequate description of changes of risk factors and, thus, keeping stable 
mean values and narrow CIs.  
Matching of the groups either 1:1 or with a propensity score provided comparable 
groups for most variables; however, there were some minor differences in baseline 
characteristics which we tried to eliminate using adjusted regression models. We used 
all the characteristics in the models and, especially for the first study, we conducted a 
sensitivity analysis to examine the potential importance of unknown factors and the 
results were unchanged. Of course, the selection of patients who need GBP may itself 
be subject to bias, increasing the effect sizes of several outcomes. This translates to 
residual confounding, which we cannot rule out from our studies. Measurement’s 
standard errors cannot also be excluded in case of more frequent follow-up of surgical 
patients than the controls. 
Finally, we did not exclude patients with multiple comorbidities, which may affect the 
results. We did this in order to maintain the power and heterogeneity of patients 
undergoing the procedure, resembling as much as possible the clinical reality of such 
interventions. Nonetheless, we described the trend of such comorbidities. 
Additionally, we only included patients undergoing GBP and not other bariatric 
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methods. This was done consciously as there is insufficient data during the study 
period and evidence of alternative methods to date. 
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6. CONCLUSION 
 
This thesis has presented the effects of GBP surgery in patients with obesity and 
T2DM as a result of the opportunities offered by two large quality register databases 
in Sweden. The first and most important finding is a more than 50% relative risk 
reduction in all-cause mortality, cardiovascular death, and fatal or non-fatal 
myocardial infarction. It is noteworthy that the best effects on cumulative mortality 
appeared with the highest BMI reductions, as well as in patients who had diabetes 
remission during the first year of follow-up, supporting the use of GBP as a credible 
therapeutic tool to impact obesity and T2DM. 
Expansion of the study on GBP to examine specific cardiovascular risk factors 
revealed significantly reduced risk for HbA1c and HDL, which followed the BMI 
reduction through the entire follow-up period, and transient changes of LDL-
cholesterol and blood pressure. These effects were significantly affected by GBP 
compared to the controls despite the lower consumption of antidiabetic, 
antihyperlipidemic, and antihypertensive agents. BMI reduction remained 
significantly lower long-term and, thus, we believe it is the most important factor to 
have a positive effect on all-cause and cardiovascular mortality. The other factors, as 
we concluded from the mediation analysis, did not have mediated effect. The risk 
reduction of fatal or non-fatal myocardial infarction could not be attributed to the 
change of any single factor. 
Apart from the beneficial effects on all-cause and cardiovascular mortality, as well as 
on myocardial infarction, we also showed lower postoperative risk of hospitalization 
due to various cardiovascular morbidities, severe kidney disease, and cancer. 
Analyses using a different cohort, but with the same characteristics and longer follow-
up, showed a higher risk of postoperative complications, i.e. 17.6% of patients needed 
additional surgical treatment after GBP. Long-term consequences of GBP that caused 
frequent hospital admission were a 2-fold higher risk of anemia, a 3-fold higher risk 
of malnutrition and alcohol abuse, and a higher incidence of psychiatric disorders. All 
these postoperative adverse effects impose a more careful screening of patients before 
undergoing GBP. 
Additionally, GBP was found to be a beneficial factor that lowers the risk of renal 
disease postoperatively in patients with obesity and T2DM. A wide spectrum of 
adverse renal parameters showed lower incidence after GBP. This association 
remained when we looked at different strata of preoperative renal function covering 
all stages of kidney insufficiency. Because of the lower power for intermediate levels 
of eGFR, we cannot derive solid conclusions, although there were beneficial effects in 
patients with normal renal function and those with the most impaired renal function. 
Except for the lower incidences of renal diagnoses, the adjusted model revealed lower 
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CVD and all-cause mortality, adding support for the importance of obesity on cardio-
renal axis.  
Loss of weight, achieved by GBP, results in numerous positive health effects, 
although there is a risk of surgical and post-operative complications. It seems 
reasonable to suggest that careful selection of patients for GBP, and optimized 
monitoring post-surgery could further improve the results of this treatment. 
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7. FUTURE PERSPECTIVES 
 
The present thesis discussed the beneficial effects of GBP in patients with obesity and 
T2DM, mainly with respect to mortality, cardiovascular risk, and kidney dysfunction, 
as well as a range of short- and long-term adverse events compared to patients not 
receiving GBP. 
GBP has been established as the most effective method of weight loss, and in order to 
continue to be applied, future studies should focus on research into new algorithms 
and metrics that could more accurately determine the indications of how and to whom 
GBP should be applied. Multidisciplinary centers with specialized teams should 
identify patients who have the need for such treatment, enhancing safety and 
efficacious monitoring postoperatively. 
It is true that other bariatric methods are developing, but research on GBP should go 
on, since it serves as a reference method. International guidelines have indeed 
incorporated bariatric surgery into the treatment of diabetes, so future research could 
focus on, e.g., the effects in various groups of patients. The observational studies of 
this thesis, involving large samples of the general population, with and without 
diabetes, can be considered as precursors of and promote prospective studies. 
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